Evidence map›Paper›PMID 32961315›Full record

ArticleThe Journal of molecular diagnostics : JMD2020

Development of a New Multiplex Real-Time RT-PCR Assay for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Detection.

Wei Zhen, Gregory J Berry

Registry-linked trialOpen access · bronzeAbstract readEvaluation Study
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05190016 (Development of a Multiplex BangasureTM RT-PCR Kit for the Detection of SARS-Corona Virus-2), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05190016 completednot on this mapstarted 2022, after this paper: background citation

Development of a Multiplex BangasureTM RT-PCR Kit for the Detection of SARS-Corona Virus-2

Typeobservational_patient_registrySponsorDR. MALA KHANRan2022 to 2022Enrolled150ConditionsCOVID-19
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Hybridization-driven fluorometric platform based on metal-organic frameworks for the identification of the highly homologous viruses.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Evaluation of "Pathogens (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Wei ZhenDivision of Infectious Disease Diagnostics, Northwell Health Laboratories, Lake Success, New York.
Gregory J BerryDivision of Infectious Disease Diagnostics, Northwell Health Laboratories, Lake Success, New York; Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York. Electronic address: gberry1@northwell.edu.
Northwell Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This research describes the development of a new multiplex real-time RT-PCR test for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with primers designed to amplify a 108 bp target on the spike surface glycoprotein (S gene) and a hydrolysis TaqMan probe designed to specifically detect SARS-CoV-2. The limit of detection (LOD) and clinical performance of this new assay were evaluated. A LOD study with inactivated virus exhibited performance equal to the modified CDC assay, with a final LOD of 1301 ± 13 genome equivalents/mL for the Northwell Health Laboratories laboratory-developed test (NWHL LDT) versus 1249 ± 14 genome equivalents/mL for the modified CDC assay. In addition, a clinical evaluation with 270 nasopharyngeal swab specimens exhibited 98.5% positive percent agreement and 99.3% negative percent agreement compared with the modified CDC assay. The NWHL LDT multiplex design allows testing of 91 patients per plate, versus a maximum of 29 patients per plate on the modified CDC assay, providing the benefit of testing significantly more patients per run and saving reagents, during a time when both of these parameters are critical. The results show that the NWHL LDT multiplex assay performs as well as the modified CDC assay but is more efficient and cost-effective and can be used as a diagnostic assay and for epidemiologic surveillance and clinical management of SARS-CoV-2.

Indexed as

Clinical Laboratory TechniquesBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 TestingCOVID-19 VaccinesDNA PrimersHumansLimit of DetectionMultiplex Polymerase Chain ReactionPandemicsPneumonia, ViralSARS-CoV-2Sensitivity and SpecificitySpike Glycoprotein, CoronavirusCovid-19 aAPC vaccineCOVID-19 VaccinesDNA PrimersSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID32961315
PMCPMC7501774
OpenAlexW3087658644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.